---
title: "Terfenadine - Vasomotor rhinitis"
sidebar: mydoc_sidebar
permalink: db00342-mesh-d012223-1.html
toc: false 
---


Path ID: `DB00342_MESH_D012223_1`
{% include image.html url="images/db00342-mesh-d012223-1.png" file="db00342-mesh-d012223-1.png" alt="db00342-mesh-d012223-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D016593 | Terfenadine | Drug |
| MESH:C093230 | Fexofenadine | ChemicalSubstance |
| UniProt:P35367 | Histamine H1 receptor | Protein |
| GO:0006954 | Inflammatory response | BiologicalProcess |
| MESH:D012223 | Vasomotor rhinitis | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Terfenadine | INCREASES ABUNDANCE OF | Fexofenadine |
| Fexofenadine | DECREASES ACTIVITY OF | Histamine H1 Receptor |
| Histamine H1 Receptor | PREVENTS | Inflammatory Response |
| Inflammatory Response | CAUSED BY | Vasomotor Rhinitis |
|---------|-----------|---------|

Comment: In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation

Reference: [https://go.drugbank.com/drugs/DB00342#mechanism-of-action](https://go.drugbank.com/drugs/DB00342#mechanism-of-action){:target="_blank"}